Citadel Advisors
GLSI icon

Citadel Advisors’s Greenwich LifeSciences GLSI Stock Holding History

Citadel Advisors’s Portfolio GLSI Stock Details GLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,830
Closed -$249K – 13441
2025
Q4 		$249K Sell
11,830
-9,112
-44% -$95.9K ﹤0.01% 10568
2025
Q3 		$208K Buy
20,942
+7,174
+52% +$81K ﹤0.01% 11180
2025
Q2 		$125K Buy
13,768
+454
+3% +$4.32K ﹤0.01% 11129
2025
Q1 		$127K Buy
+13,314
New +$161K ﹤0.01% 11127
2023
Q2 		– Sell
-10,354
Closed -$143K – 14662
2023
Q1 		$143K Buy
+10,354
New +$164K ﹤0.01% 10723
2022
Q3 		– Sell
-17,657
Closed -$150K – 12982
2022
Q2 		$150K Buy
+17,657
New +$202K ﹤0.01% 10982
2021
Q2 		– Sell
-7,114
Closed -$243K – 13950
2021
Q1 		$243K Buy
+7,114
New +$242K ﹤0.01% 11304

Other funds holding GLSI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Citadel Advisors's GLSI Position: Q1 2026 in Review

Citadel Advisors sold out of Greenwich LifeSciences (GLSI) in Q1 2026, closing a stake of 11,830 shares — an estimated $249K sold.

Citadel Advisors first reported a position in GLSI in Q1 2021 and held it in 7 quarters. The position peaked at $249K in Q4 2025. 64 funds tracked by Wall St. Rank hold GLSI as of Q1 2026.

  • Citadel Advisors reported no remaining Greenwich LifeSciences position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 11,830 Greenwich LifeSciences shares in Q1 2026, an estimated $249K.
  • Citadel Advisors first reported a position in Greenwich LifeSciences in Q1 2021 and held it in 7 quarters.
  • Citadel Advisors's Greenwich LifeSciences position peaked at $249K in Q4 2025.
  • 64 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.